TuisAIMI • OTCMKTS
add
AIM ImmunoTech Inc
Vorige sluiting
$0,085
Dagwisseling
$0,079 - $0,090
Jaarwisseling
$0,025 - $0,12
Markkapitalisasie
6,13 m USD
Gemiddelde volume
300,82 k
P/V-verhouding
-
Dividend-opbrengs
-
Primêre beurs
OTCMKTS
Marknuus
Finansieel
Inkomstestaat
Inkomste
Netto inkomste
| (USD) | Mrt. 2025info | J/J-verandering |
|---|---|---|
Inkomste | 16,00 k | -60,00% |
Bedryfskoste | 3,62 m | -37,13% |
Netto inkomste | -3,70 m | 36,31% |
Netto winsgrens | -23,16 k | -59,23% |
Wins per aandeel | -0,05 | 58,33% |
EBITDA | -3,56 m | 37,26% |
Effektiewe belastingkoers | — | — |
Balansstaat
Totale bates
Totale aanspreeklikheid
| (USD) | Mrt. 2025info | J/J-verandering |
|---|---|---|
Kontant en korttermynbeleggings | 2,25 m | -79,46% |
Totale bates | 6,25 m | -61,41% |
Totale aanspreeklikheid | 10,10 m | -11,07% |
Totale ekwiteit | -3,86 m | — |
Uitstaande aandele | 76,42 m | — |
Prys om te bespreek | -1,70 | — |
Opbrengs op bates | -121,80% | — |
Opbrengs op kapitaal | -6 371,48% | — |
Kontantvloei
Netto kontantverandering
| (USD) | Mrt. 2025info | J/J-verandering |
|---|---|---|
Netto inkomste | -3,70 m | 36,31% |
Kontant van bedrywe | -2,36 m | 50,97% |
Kontant van beleggings | 898,00 k | 668,35% |
Kontant van finansiering | 660,00 k | -76,67% |
Netto kontantverandering | -803,00 k | 62,55% |
Beskikbare kontantvloei | -1,82 m | 34,19% |
Meer oor
AIM ImmunoTech Inc., formerly known as Hemispherx Biopharma Inc., is a biopharmaceutical company based in Ocala, Florida that is focused on the research and development of therapeutics to treat multiple types of cancers, various viruses and immune-deficiency disorders. Founded in 1990, the company has twenty-three employees.
The company has created an immunomodulatory double stranded RNA drug called Ampligen.
It is also developing Ampligen to use as a treatment for multiple cancer tumor types, COVID-19 and chronic fatigue syndrome. Wikipedia
Gestig
1966
Webwerf
Werknemers
22
